Table 1

Patients’ demographics and baseline clinical characteristics

No. (%)All patients (124)
Median age, years (range)46 (23–73)
Sex (male/female)
 Male95 (76.6)
 Female29 (23.4)
ECOG performance status score
 035 (28.2)
 189 (71.8)
Smoking
 Never85 (68.6)
 Former/current35 (28.2)
 Unknown4 (3.2%)
Stage
 Primary metastasis13 (10.5)
 Recurrent with distant metastasis111 (89.5)
WHO histological classification
 Undifferentiated non-keratinised96 (77.4)
 Differentiated non-keratinised14 (11.3)
 Keratinised squamous carcinoma14 (11.3)
Distant metastasis sites
 Lung69 (55.6)
 Liver69 (55.6)
 Bone50 (40.3)
 Distant lymph46 (37.1)
 Others17 (13.7)
 None8 (6.5)
Prior lines for advanced disease
 142 (33.9)
 235 (28.2)
 325 (20.2)
 4 or more22 (17.7)
Prior chemotherapy for advanced disease
 Paclitaxel74 (59.7)
 Gemcitabine69 (55.6)
 5-Fluoracial52 (41.9)
 Docetaxel37 (29.8)
 Tegafur25 (20.2)
 Cetuximab23 (18.5)
 Capecitabine19 (15.3)
 Ipilimumab8 (6.5)
Comorbidity
 Yes83 (66.9)
 No41 (33.1)
Prior radiation
 Yes111 (89.5)
 No13 (10.5)
WES detection
 Yes60 (48.4)
 No64 (51.6)
  • ECOG, Eastern Cooperative Oncology Group; WES, whole-exome sequencing; WHO, world health organization.